
Dr. Lal Path Labs Ltd. share price
NSE: LALPATHLAB · Healthcare
₹2,000.70 +0.39%
Closing price data, updated 17 Nov 2026. 52-week range: -3.8% from high, +57.2% above low.
Price₹2,000.70
Market cap₹33,454 Cr
P/E57.3
P/B12.19
ROE21.6%
ROCE25.7%
Debt / equity0.08
Dividend yield0.00%
EPS₹34.90
Book value₹164.13
Operating margin37.1%
Dipscan score53 / 100
Share: WhatsAppX / TwitterTelegram
Dr. Lal Path Labs Ltd. shareholding pattern
As of Sep 2026: Promoters 52.93%, FIIs 18.73%, DIIs 21.58%, Government 0.00%, Public 5.30%, Others 1.46%.
| Holder | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|---|
| Promoters | 52.93% | 53.19% | 53.21% | 53.21% | 53.21% | 53.79% |
| FIIs | 18.73% | 17.36% | 17.18% | 20.29% | 21.86% | 21.68% |
| DIIs | 21.58% | 21.59% | 21.38% | 19.21% | 18.49% | 17.91% |
| Government | 0.00% | 0.01% | 0.01% | 0.01% | 0.00% | 0.00% |
| Public | 5.30% | 6.25% | 6.54% | 5.82% | 5.19% | 5.23% |
| Others | 1.46% | 1.60% | 1.67% | 1.47% | 1.25% | 1.38% |
| No. of Shareholders | 113,559 | 111,037 | 114,527 | 114,385 | 112,703 | 118,656 |
As filed by the company with the exchanges.
Returns
| 1 day | 1 week | 1 month | 3 months | 6 months | 1 year |
|---|---|---|---|---|---|
| +0.39% | +1.56% | +3.24% | +1.64% | +25.04% | +30.59% |
Growth
| Sales growth, 3 years | +11.1% |
| Sales growth, 5 years | – |
| Profit growth, 3 years | +28.3% |
| Profit growth, 5 years | – |
| Latest quarter sales vs last year | – |
| Latest quarter profit vs last year | – |
Strengths and weaknesses
Strengths
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 36.4%
Weaknesses
- Stock is trading at 12.2 times its book value
- The company has delivered a poor sales growth of 11.8% over past five years.
Peers in Healthcare
| Company | Price | Market cap | P/E | ROE | 1 year |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | ₹1,867.50 | ₹4,48,076 Cr | 40.9 | 14.7% | +8.8% |
| Divi's Laboratories Ltd. | ₹11,080.00 | ₹2,94,139 Cr | 87.5 | 16.2% | +69.4% |
| Torrent Pharmaceuticals Ltd. | ₹4,691.20 | ₹1,78,438 Cr | 84.0 | 27.1% | +22.6% |
| Apollo Hospitals Enterprise Lt | ₹8,771.00 | ₹1,26,114 Cr | 56.2 | 21.9% | +16.9% |
| Laurus Labs Ltd. | ₹2,220.00 | ₹1,19,949 Cr | 89.5 | 18.2% | +125.2% |
| Zydus Lifesciences Ltd. | ₹1,192.00 | ₹1,18,902 Cr | 28.4 | 19.7% | +27.0% |
| Dr. Reddy's Laboratories Ltd. | ₹1,377.90 | ₹1,14,778 Cr | 41.0 | 12.1% | +13.7% |
| Cipla Ltd. | ₹1,394.50 | ₹1,12,658 Cr | 38.9 | 11.8% | -8.0% |
Frequently asked questions
What is the share price of Dr. Lal Path Labs Ltd.?
Dr. Lal Path Labs Ltd. (LALPATHLAB) last closed at ₹2,000.70 (+0.39% on the day).
What is the market cap of Dr. Lal Path Labs Ltd.?
About ₹33,454 Cr.
What is the P/E ratio of Dr. Lal Path Labs Ltd.?
The price-to-earnings ratio is 57.3, and return on equity is 21.6%.
Figures are calculated from company results and exchange prices and are for information only.